Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Concern over medical tests

24.07.2006
Genetic tests which aim to provide information on individual responses to drugs are being regulated in a confusing and possibly dangerous way, say UK researchers. The UK Pharmacogenetics Study Group, a group of collaborating scientists from Sussex, Plymouth, Cambridge, York, Exeter and Nottingham universities are calling for careful changes to EU regulations to protect patients.

Pharmacogenetics is the study of genetic variation and its influence on people's different responses to drugs. Each individual has a unique genetic makeup, and increasingly clinicians are performing pharmacogentic tests in an attempt to predict how a patient will react to treatment. But a new study has concluded that the lack of regulation of these tests, coupled with the fact that they offer only incomplete information, could pose serious risks to patients.

"Pharmacogenetic tests can tell you the extent to which a particular person can metabolise a drug," explains Dr Michael Hopkins, a Research Fellow at SPRU Science and Technology Research at the University of Sussex. "But they don't ensure that a person won't have a negative reaction, because not all toxic reactions are due to genetic traits. Similarly, these tests can tell you if someone has a mutation that may be relevant to a condition. But they don't tell you whether or not this link is tight enough to base prescription information on it. Importantly, this latter step is the bit that isn't covered by regulation. If tests are not fully validated, people will be prescribed drugs that are inappropriate," he says.

"The problem is that pharmacogenetic tests are lumped together with the regulations of all the other genetic tests," says Dr Adam Hedgecoe, a Senior Lecturer in the Sociology Department in the University of Sussex. "European legislation classifies pharmacogenetics as low risk, meaning that they are not overseen by regulatory authorities."

"What we need to do is to introduce a degree of discrimination into the European legislation; to accept that pharmacogenetic tests are not necessarily low risk and to acknowledge that the safety or risks associated with these tests must be judged in their own terms," he says.

The team describe their concerns in their report, "Policy Issues in Pharmacogenetics", which is to be published today following a number of research projects funded by the Wellcome Trust. This finding - and a number of others - are the result of extensive qualitative research over the last 6 years, including interviews with over 300 clinicians, scientists, policymakers, industrialists and regulators in the UK, US and Europe, and analysis of company reports and other information from the largest academic database on the genomics industry, created by team member Paul Martin, at Nottingham University.

"Our conclusions have been drawn based on actual evidence, rather than just a concern or worry," says Hedgecoe. "They are based on what companies are actually doing. We have looked at that the large companies are not investing in: pharmacogenetic tests for drugs already on the market. It is only possible to do this with studies that are based on actual evidence."

"As for the European legislation, as far as I am aware, we are the first to raise the issue of the danger of lumping pharmacogenetic tests with other genetic tests." says Hedgecoe.

Dr Adam Hedgecoe | alfa
Further information:
http://www.york.ac.uk/res/pgx/publications/

More articles from Life Sciences:

nachricht Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>